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Abstract
The affinity of the poly(ADP-ribose) polymerase-1 (PARP-1) for platinum-damaged DNA was first
discovered during photo-crosscroxss-linking experiments using the photoactive compound Pt-BP6
(Zhang, C. X.; Chang, P. V.; Lippard, S. J., J. Am. Chem. Soc. 2004, 126, 6536–6537), an analogue
of the anticancer drug cis-diammine-dichloroplatinum(II), cisplatin. Although PARP inhibitors
sensitize cancer cells to cisplatin, there are conflicting reports in the literature about their efficacy.
In order to improve our understanding of the mechanism by which PARP inhibition might potentiate
the cell-killing ability of cisplatin, and to shed light on the source of the discrepancy among different
laboratories, we have in the present study probed the influence of three PARP inhibitors in four types
of cancer cells, cervical (HeLa), testicular (NTera2), pancreatic (BxPC3) and osteosarcoma (U2OS),
on the results of Pt-BP6 photo-cross-linking experiments and cytotoxicity assays. We find that the
activity of PARP proteins following exposure to platinum-modified DNA results in the dissociation
of DNA-bound proteins. PARP inhibitors were able to sensitize some, but not all, of the cell lines to
cisplatin. This cell-line dependence and the potential consequences of PARP-initiated protein
removal from platinum-DNA lesions are discussed. Control experiments revealed that NTera2 cells
are especially sensitive to PARP inhibition.
INTRODUCTION
The compound cis-diamminedichloroplatinum(II), or cisplatin, is one of the most successful
anticancer agents ever discovered. Cisplatin has been used widely to treat a variety of tumor
types for more than thirty years.1 Platinum-based therapies remain at the forefront of the fight
against cancer, and new strategies are being developed including delivery systems2 and
combination therapies.3 Cisplatin kills cells by binding to DNA and blocking template-
dependent activities, notably transcription. The most common types of cisplatin-DNA adducts
found in patients treated with the drug are 1,2-d(GpG), 1,2-d(ApG), and 1,3-d(GpNpG)
intrastrand cross-links, in which one platinum atom binds to the N7 atoms of the two purine
bases.1 These platinum-DNA cross-links are recognized by many nuclear proteins, which can
signal repair of the adducts, or conversely, lead to cell death.4
The affinity of poly(ADP-ribose) polymerase-1 (PARP-1) for platinum 1,2-d(GpG) and 1,3-d
(GpTpG) intrastrand cross-links on duplex DNA was recently discovered.5,6 The activity of
the PARP superfamily of proteins has been implicated in DNA repair, chromatin remodeling,
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transcriptional control, and inflammation.7 PARP-1 is a 113 kDa protein that contains a DNA-
binding domain with two zinc fingers, an automodification domain, and a catalytic domain.
The catalytic domain binds nicotinamide adenine dinucleotide (NAD+) and creates long,
branched PAR chains in which each unit contains two negatively charged phosphate linkers
(Figure 1A). These polymers can be digested by poly(ADP-ribose) glycohydrolase (PARG)
to the unmodified form of the protein.7
Upon exposure of cells to DNA-damaging agents, PARP proteins are strongly activated. PARP
can activate three different cellular pathways (Figure 2).8 Under mild conditions, PARP
proteins mediate DNA damage repair. PARP-1 activity has been implicated in base excision
repair (BER)9 and in a backup pathway for nonhomologous end-joining (NHEJ) repair of
double-strand breaks.10,11 When DNA damage is too severe to be repaired efficiently, the
PAR polymers created by PARP proteins signal the release of apoptosis-inducing factor (AIF)
from mitochondria, which initiates apoptosis.12 Apoptosis induced by cisplatin is due to both
caspase- and AIF-dependent signaling mechanisms.13 Under severe DNA damage conditions,
the activity of PARP proteins depletes cellular reservoirs of NAD+, leading to the shutdown
of glycolysis. Because cancer cells rely on glycolysis for ATP production, they die by necrosis.
14
The attachment of PAR polymers to proteins is an important component of several biochemical
pathways. Automodified PARP-1 interacts with XRCC1, which may be responsible for the
initiation of base excision repair.7 A PAR-binding motif has been identified in several DNA
repair proteins, and this type of domain is present in core histones, p53, DNA topoisomerase
I, Ku70, XPA, Msh6, DNA Ligase III, and XRCC1.15–17 Negatively charged PAR polymers
create an electrostatic repulsion between the proteins they modify and polyanionic DNA
(Figure 1B). For example, poly(ADP-ribosyl) ation of histones contributes to chromatin
relaxation, making damaged DNA more accessible to repair proteins.7 The C-terminal domain
of the chromatin remodeling protein HMGB1 is poly(ADP-ribosyl)ated by PARP-1, causing
it to dissociate from chromatin and translocate to the cytosol.18,19
Previous studies to understand PARP activity following DNA damage have focused on DNA
methylating agents, such as N-methyl-N-nitro-N-nitrosoguanidine (MNNG).12,20–22 The
activity of PARP following cellular exposure cisplatin is less well understood. One study
revealed increased levels of PAR polymers upon cisplatin treatment of rat and monkey tumor
cells, which was attributed to DNA double-strand break formation during the processing of
cisplatin-DNA adducts.23 Another report demonstrated that PARP activity is strongly
upregulated following exposure of renal tubular cells to cisplatin, significantly depleting ATP
levels within these cells.24 In this work, extremely high concentrations of cisplatin (0.5 mM)
were required to induce PARP activity. Recently, a mild increase in PARP activity was reported
24 h after a 4-h treatment of HT29 colon carcinoma cells 10 µM cisplatin.25 Only one cell line
was tested using the assay, however, providing little information about the importance of PARP
activity in cisplatin sensitivity. HeLa cervical cancer cells were also employed in this study,
but PARP activity following cisplatin treatment was not reported.25 Although the activation
of PARP upon cisplatin treatment is not well characterized, PARP inhibitors sensitize cells to
cisplatin. The compound CEP-6800 (B, Figure 3) sensitizes non-small cell lung carcinoma
cells to cisplatin in both culture and xenografts.26 Another newly developed PARP inhibitor,
ABT-888 (D, Figure 3), substantially improves tumor response to cisplatin and carboplatin.
27 The anticancer potential of PARP inhibitors and platinum drugs in combination therapies
is currently being investigated in phase I and II clinical trials.28
Previously we reported the ability of PARP-1 to bind to platinum-damaged DNA with the use
of a novel photo-cross-linking probe.5,6 Photo-cross-linking is achieved by exposing duplex
DNA containing a site-specific adduct of a photoactive cisplatin analogue to nuclear extracts
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from cancer cells. The photoactive compound is cis-[Pt(NH3)(N-(6-aminohexyl)-4-
benzophenonamide)Cl2] (Pt-BP6, Figure 4A), which contains a benzophenone moiety tethered
to the platinum atom by a hexamethylene linker. Irradiation at 360 nm activates the
benzophenone, ultimately leading to covalent bond formation between the platinum-modified
DNA and any proteins in the vicinity of the platination site. The products are then resolved by
gel electrophoresis, which separates protein-platinum-DNA complexes according to their size.
For analytical-scale experiments, radiolabeled DNA allows the protein-Pt-DNA complexes to
be visualized by audioradiography (Figure 4B).
In the present work, the role of PARP proteins in mediating cisplatin cytotoxicity has been
investigated in a number of cell lines with varying sensitivities to cisplatin. Included are
cervical (HeLa), testicular (NTera2), pancreatic (BxPC3) and osteosarcoma (U2OS) cells. Two
previously reported PARP inhibitors were prepared according to literature protocols,29–31
and one step in the synthesis was improved. Photo-cross-linking experiments were preformed
in the presence of one of these PARP inhibitors to determine its effect on the binding of nuclear
proteins to platinum-damaged DNA. The results indicate that PARP activity in the presence
of platinum-damaged DNA induced dissociation of the nuclear proteins from the duplex. In
addition, we investigated these two PARP inhibitors for their ability to potentiate cisplatin
cytotoxicity in the four cell lines. For comparison purposes, the commercially available and
well-characterized PARP inhibitor, 4-ANI, was also evaluated. The commercially available
PARP inhibitor, 4-ANI, was also used in these studies to confirm that our synthesized
compounds behave similarly to a well-characterized PARP inhibitor. The results indicate that
the ability of PARP inhibitors to sensitize cells to cisplatin is cell-line-dependent, an effect that
may derive from the nature of PARP activity in the presence of platinum-modified DNA.
MATERIALS AND METHODS
All reactions were performed in oven- or flame-dried round bottom flasks. The flasks were
fitted with rubber septa and reactions were conducted under a positive pressure of argon.
Stainless steel cannulae or gas-tight syringes were used to transfer air- and moisture-sensitive
liquids. Flash column chromatography was performed32 using silica gel (60-Å pore size, 32–
63 µm, standard grade). Analytical thin–layer chromatography was carried out by using glass
plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent
indicator (254 nm). Thin layer chromatography plates were visualized by exposure to UV light
and an aqueous solution of ceric ammonium molybdate (CAM). Organic solutions were
concentrated on rotary evaporators at ~20 Torr (house vacuum) at 25–35 °C. Commercial
reagents and solvents were used as received with the following exceptions; dichloromethane,
diethyl ether, tetrahydrofuran, and triethylamine were purified as described33 under a positive
argon pressure. 1,4-Dioxane (>99.9 % HPLC grade, ≤0.020 % water) and Raney nickel (W.R.
Grace and Co. Raney® 3202, slurry, in H2O, active catalyst) were used as received.
Proton nuclear magnetic resonance (1H NMR) spectra were recorded at the MIT Department
of Chemistry Instrumentation Facility (DCIF) with an inverse probe 500 MHz spectrometer
and are referenced from the residual protium in the NMR solvent peaks (DMSO–d5, δ
2.50). 13C NMR spectra were recorded at 125 MHz and referenced from the carbon resonances
of the solvent (DMSO–d6, δ 39.52). High-resolution mass spectra were obtained at the DCIF
using a Fourier transform ion cyclotron resonance mass spectrometer with electrospray
ionization.
Synthesis of 4,5,6,7-tetrahydro-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione (A)
To a pale yellow solution of 3a,3b,4,5,6,6a,7,11c-octahydro-1H-cyclopenta[a]pyrrolo[3,4-c]
carbazole-1,3(1H)-dione (E)29 (125 mg, 0.446 mmol, 1 equiv) in 1,4-dioxane (8.1 mL) was
added γ-MnO234 (970 mg, 11.2 mmol, 25.0 equiv) and the resulting black suspension was
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heated to reflux. After 7 h, the suspension was allowed to cool to approximately 60 °C, diluted
with THF (4 mL), sonicated for 1 min, and filtered through a plug of celite (diameter 4.0 cm,
height 3.5 cm) that was pre-wetted with THF. The reaction flask and plug were rinsed with
additional portions of warm tetrahydrofuran (40–50°C, 75 mL total volume), and the clear
yellow filtrate was concentrated to give A29 (60.5 mg, 49%) as a bright yellow solid. 1H NMR
(DMSO–d6) δ ppm: 11.91 (s, 1H), 10.93 (s, 1H), 8.80 (d, J = 7.5 Hz, 1H), 7.56 (d, J = 8.0 Hz,
1H), 7.51 (t, J = 7.7 Hz, 1H), 7.27 (t, J = 7.7 H, 1H), 3.23 (t, J = 7.5 Hz, 2H), 3.15 (t, J = 7.5
Hz, 2H), 2.27 (quintet, J = 7.5 Hz, 2H). 13C NMR (DMSO–d6) δ ppm: 171.8, 171.8, 142.7,
141.4, 139.8, 133.2, 128.7, 126.5, 125.7, 121.8, 121.1, 120.8, 118.6, 112.7, 31.9, 30.8, 26.3.
Synthesis of 10-(aminomethyl)-4,5,6,7-tetrahydro-1H-cyclopenta[a]pyrrolo[3,4-c]
carbazole-1,3(2H)-dione (B)
This compound was prepared as described in the literature.29 A suspension of 2-(1,3-
dioxo-2,3,4,5,6,7-hexahydro-1H-cyclopenta-[a]pyrrolo[3,4-c]carbazol-10-yl)acetonitrile29
(47.0 mg, 0.156 mmol, 1 equiv) and Raney nickel (W.R. Grace and Co. Raney® 3202, slurry,
in H2O, active catalyst, 250 mg, 532 wt. %) in dimethylformamide (5.0 mL) was saturated
with ammonia by passage of a stream of ammonia gas (1 atm) for 10 min. The reaction vessel
was placed in a hydrogenation apparatus and the apparatus was purged three times with
dihydrogen (60 psi), then maintained under dihydrogen (60 psi) with vigorous stirring of the
reaction mixture. After 48 h, the hydrogenation apparatus was opened and an additional portion
of Raney nickel (250 mg, 532 wt. %) was added, the suspension was purged with ammonia
gas (1 atm) for 10 min, and the vessel was purged with H2 (3 × 60 psi) then maintained under
H2 (60 psi). After an additional 48 h another portion of Raney Nickel (250 mg, 532 wt. %) was
added in the same fashion, and the reaction mixture was maintained under H2 (60 psi) for 96
h. The reaction mixture was gently vacuum-filtered through a plug of celite (diameter 2.5 cm,
height 2.5 cm) that was pre-wetted with dimethylformamide, and the reaction flask and celite
were rinsed with additional portions of dimethylformamide (35 mL total). The bright yellow
filtrate was concentrated to a yellow residue, which was dissolved in aqueous HCl (0.021 N,
30 mL). The aqueous solution was washed with ethyl acetate (2 × 15 mL) prior to lyophilization
to give B29 (5.5 mg, 12%) as a bright yellow solid. 1H NMR (DMSO–d6) δ ppm: 12.17 (s,
1H), 11.00 (s, 1H), 8.82 (s, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 4.16 (m,
2H), 3.23 (t, J = 7.2 Hz, 2H), 3.16 (t, J = 7.2 Hz, 2H), 2.27 (quintet, J = 7.5 Hz, 2H). HRMS–
ESI (m/z): calcd for C18H15N3O2Na [M + Na]+: 328.1056, found: 328.1050.
Cell culture
HeLa, NTera2, BxPC3, and U2OS cells were grown in DMEM with 10% FBS at 37 °C in an
atmosphere of 5% CO2. HeLa YS cells were prepared as previously described5 and grown in
DMEM with 10% FBS supplemented with 100 µg/mL zeocin selection reagent (Invitrogen).
Nuclear extracts were prepared as previously described.5,6
Photo-cross-linking in the presence of PARP inhibitors
Photo-cross-linking experiments were carried out as previously described.5,6 A 25-bp DNA
duplex containing a site-specific 1,2-d(GpG) or 1,3-d(GpTpG) intrastrand cross-link of Pt-BP6
was exposed to HeLa nuclear extracts in the presence of 0, 0.01, 0.05, 0.1, 0.3, or 1.0 µM CEP-
A prior to photo-cross-linking. The inhibitor was dissolved in DMF and diluted to the desired
concentration with the final solution containing 0.02% DMF. Photo-cross-linking was also
performed without DMF as a control. Photo-cross-linking experiments were then repeated
using nuclear extracts from NTera2, BxPC3, U2OS, and HeLa YS cell lines, with or without
1.0 µM CEP-A, for both types of Pt-BP6 cross-link. The audioradiographs were
quantitatedquantified using ImageQuant data analysis software.
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HeLa, NTera2, BxPC3 and U2OS cells were plated at 500–1000 cells/well in a 96-well plate.
The following day, the cells were treated with varying concentrations of PARP inhibitors CEP-
A (A), CEP-6800 (B), and 4-amino-1,8-naphthalimide (4-ANI, C) to determine the maximum
tolerated dose of inhibitor in each cell line. After 96 h, the viability of the cells was assed by
the MTT assay. To each well was added 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and the plates were incubated at 37 °C for four h. The
media was revomed from each well by vacuum, and replaced with 100 µL of DMSO. The
number of viable cells was determined by measuring the absorbance of each well at 562 nm.
The cytotoxicity assays were then repeated with the maximum tolerated dose of PARP inhibitor
plus varying concentrations of cisplatin.
RESULTS
Overview
The effect of PARP inhibition on the ability of nuclear proteins to bind platinum-modified
DNA was assessed using photo-cross-linking experiments5,6 in which a radiolabeled 25-bp
duplex DNA containing a site-specific adduct of a photoactive analogue of cisplatin is
incubated with nuclear extracts from cancer cells and then irradiated at 360 nm. Such irradiation
causes a covalent bond to be formed between the platinum-modified DNA and a nearby bound
protein (Figure 4). Previous work of this kind identified several proteins that bind to platinum-
modified DNA, including PARP-1.5,6 In the present study, the addition of a PARP inhibitor
CEP-A (A, Figure 3) to the photo-cross-linking reaction increased the total photo-cross-linking
yield. The extent of this effect varied between cell lines and platinum cross-links tested. The
ability of PARP inhibitors to sensitize the cell lines to cisplatin was also assessed.
Synthesis of CEP-A (A) and CEP-6800 (B)
Pyrrolocarbazole compounds A and B were prepared according to the concise approach in the
literature29–31 (Scheme S.1, Supporting Information). In this sequence, in situ N-
carboxylation of indole followed by directed lithiation at C2 and trapping with cyclopentanone
provided the corresponding tertiary alcohol,35 which underwent dehydration upon treatment
with hydrochloric acid. Subsequent [4+2] cycloaddition with maleimide upon heating a finely
dispersed solid mixture afforded the adduct E.
Double dehydrogenation of E using 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) as an
oxidant provided the pyrrolocarbazole product containing varying amounts of inseparable
DDQ derived byproducts. Alternatively, in a procedure optimized during this work, heating a
mixture of E and freshly prepared γ-MnO234 in refluxing 1,4-dioxane cleanly provided
pyrrolocarbazole A as a bright yellow solid after simple filtration of the hot reaction mixture.
Subsequent introduction of the methylamino group was performed as previously described.
29 Regioselective bromination, coupling of the bromide with copper cyanide, and
hydrogenation using Raney nickel in the presence of ammonia provided the primary amine
B. Isolation of B as a hydrochloric acid salt was achieved by extraction into aqueous solution
and lyophilization. Spectral properties of A and B were identical to those reported previously.
29
Photo-cross-linking in the presence of the PARP inhibitor CEP-A (A)
Photo-cross-linking experiments were not affected by the presence of 0.02% DMF, necessary
to dissolve the PARP inhibitor CEP-A (Figure 5). For a 25-bp DNA duplex containing a 1,2-
d(GpG) adduct of Pt-BP6 in HeLa nuclear extracts, increasing amounts of CEP-A (A) in the
photo-cross-linking experiment resulted in a decrease in intensity of high-molecular weight
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band 7, and band 6 directly below increased in intensity (Figure 5). The proteins present in
these bands, identified and discussed in previous work,5,6 are labeled on the figure. For the
25-bp DNA containing a Pt-BP6 1,3-d(GpTpG) cross-link, PARP inhibition caused no
significant effect on any of the bands (Figure 5).
These experiments were repeated with 1 µM CEP-A (A) using nuclear extracts from HeLa,
NTera2, BxPC3, U2OS, as well as HeLa cells in which PARP-1 has been silenced using RNAi
(HeLa YS, Figure 6 and Figure 7). The behavior of the high-molecular weight bands for the
duplex containing a 1,2-d(GpG) intrastrand cross-link with HeLa nuclear extracts was
consistent with the foregoing results, but for nuclear extracts from the other cell lines, the
behavior was different (Figure 6). The total amount of photo-cross-linking for this probe
increased upon addition of the PARP inhibitor for all cell lines tested by 20–100% of the
original intensity (Figure 6 and Figure 8). Consistent with the experiment using HeLa nuclear
extracts presented in Figure 6, the addition of CEP-A (A) did not significantly affect the photo-
cross-linking of the duplex containing a 1,3-d(GpTpG) intrastrand cross-link in nuclear extracts
from any of the cell lines tested (Figure 7). The total amount of photo-cross-linking by the 1,3-
d(GpTpG) probe increased upon addition of the PARP inhibitor, but to a lesser degree than for
the 1,2-d(GpG) probe. These results are presented graphically in Figure 8.
Cytotoxicity assays
The toxicity of PARP inhibitors was investigated for each cell line to determine the maximum
tolerated dose (Figure S.1 and Table S.1, Supporting Information. These values were calculated
by evaluating the highest concentration at which at least 90% of the cells survive. The
compound CEP-A was toxic even at 0.1 µM in all cell lines (Figure S.1). Despite this toxicity,
cells co-treated with 0.1 µM CEP-A and cisplatin behaved in an identical manner to those co-
treated with nontoxic doses of the other inhibitors, as discussed below (Figure 9).
Cells were treated with the maximum tolerated dose of inhibitor and varying concentrations
of cisplatin. The results of the MTT assays are presented in Figure 9 and summarized in Table
1. The sensitivity of HeLa and NTera2 cells to cisplatin was unchanged by addition of PARP
inhibitors, but BxPC3 and U2OS cells were sensitized to cisplatin by factors of 1.6 and 3.3,
respectively.
IV. DISCUSSION
PARP-1 activity dissociates proteins from platinum-modified DNA in nuclear extracts
The activity of poly(ADP-ribose) polymerase (PARP) proteins in the presence of DNA damage
can lead to repair or, conversely, signal cell death (Figure 2). It was recently discovered that
PARP-1 binds to platinum-modified DNA.5,6 PARP-1 and the PARP family catalyze the
addition of poly(ADP-ribose) (PAR) polymers onto acceptor proteins in a reaction that
consumes NAD+ (Figure 1A).15 Each unit of the polymer contains two negatively charged
phosphate moieties, which can electrostatically repel DNA molecules from PAR-modified
proteins (Figure 1B).7 PARP-1 automodification leads to dissociation of the enzyme from
DNA, and the protein can also catalyze the modification other proteins, including histones,
which relaxes histone-DNA interactions.15 In the present work, we studied the consequences
of PARP activity upon exposure of nuclear proteins to platinum-modified DNA using photo-
cross-linking experiments.
The method utilizes DNA containing a site-specific adduct of a benzophenone-modified
cisplatin analogue Pt-BP6. Photo-cross-linking with such probes enables the study of nuclear
proteins that bind to platinum-modified DNA (Figure 4). Several platinum-modified DNA-
binding proteins have been identified in this manner, as discussed elsewhere.5,6 Here we
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performed photo-cross-linking experiments in the presence of the PARP inhibitor CEP-A
(A). The addition of CEP-A (A) to nuclear extracts prior to photo-cross-linking generally
increased the amount of proteins photo-cross-linked to Pt-BP6-modified DNA (Figure 6–
Figure 8). This result is consistent with a model in which PARP activity stimulated by platinum-
DNA cross-links results in the PAR-modification of DNA-binding proteins, causing them to
dissociate from the duplex (Figure 1B).7 Inhibition of PARP activity by CEP-A (A) eliminates
this effect, resulting in more stable protein-DNA interactions and, consequently, increased
amounts of photo-cross-linking.
Our experiments indicate that the addition of PARP inhibitor significantly increases the photo-
cross-linking of proteins to the platinum-modified DNA containing a 1,2-d(GpG) intrastrand
adduct of Pt-BP6 in each type of nuclear extract examined except for HeLa (Figure 6 and Figure
8). Nuclear extracts from HeLa cells exhibited only a modest increase in photo-cross-linking
following addition of the PARP inhibitor (Figure 5, Figure 6 and Figure 8). In these nuclear
extracts exclusively, a high molecular weight band decreases in intensity with the addition of
PARP inhibitor (Figure 5, band 7). This result indicates that PARP-1 activity in HeLa extracts
following exposure to platinum-damaged DNA is unique.
Photo-cross-linking was more significantly affected for the 1,2-d(GpG) than the 1,3-d(GpTpG)
intrastrand cross-link (Figure 6–Figure 8). This effect was consistent across all cell lines tested,
although to a lesser degree for BxPC3 extracts, indicating that the 1,2-d(GpG) intrastrand cross-
link more efficiently activates the protein. Experiments using extracts from HeLa cells in which
PARP-1 has been silenced with RNAi (HeLa YS) reveal an increase in photo-cross-linking,
similar to the behavior of NTera2, BxPC3 and U2OS cellular extracts. This result most likely
indicates that, in the PARP-1-silenced cell line, other PARP isoforms are present having the
same activity as PARP-1.
NTera2 cells are sensitive to PARP inhibition
The toxicities of three PARP inhibitors (Figure S.1, Supporting Information) were first
determined for the cell lines tested to obtain the maximum tolerated dose that could be used to
potentiate the cell-killing ability of cisplatin. NTera2 cells are extremely sensitive to PARP
inhibitors, behavior that hampers our ability to assess their capacity to enhance cisplatin
sensitivity. This finding is perplexing given that NTera2 cells express high levels of
PARP-1.5 PARP-1 is commonly mutated in germ cells, specific variants being Val762Ala and
Lys940Arg, two residues in the catalytic domain of the protein.36 Compromised activity of
the enzymeprotein by these mutations may render it especially sensitive to PARP inhibitors.
It is also possible that NTera2 cells are deficient in certain DNA repair pathways that could
strongly sensitize themlead to a strong sensitivity to PARP inhibitors, as for similar to BRCA-
mutated cancers.37 The reliance of NTera2 cells on PARP activity, even without the addition
of DNA-damaging agents, warrants further investigation.
The potentiation of cisplatin sensitivity by PARP inhibitors is cell line-dependent
Reports in the literature demonstrate that certain cell lines are unaffected by the presence of
PARP inhibitors, whereas others are sensitized to cisplatin. For example, PARP inhibitors were
unable to sensitize human ovarian tumor cell lines SK-OV-3, OAW-42, and the rat ovarian
tumor cell line O-342 to cisplatin,38 but could sensitize B16F10 murine melanoma, 9L rat
glioma, HCT-116 human colon carcinoma, DOHH-2 human B-cell lymphoma, MX-1 human
breast carcinoma, and Calu-6 human non-small cell lung carcinoma cells to the drug.26,27 The
use of new PARP inhibitors CEP-6800 (B, Figure 3) and ABT-888 (D, Figure 3) for
experiments involving the B16F10, 9L, HCT-116, DOHH-2, MX-1, and Calu-6 cell lines is
one reason for this discrepancy, because these compounds are more water soluble and are able
to enter cells and more efficiently inhibit PARP proteins.26,27 The present work demonstrates
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that there is a cell line dependence to this effect. Testicular (NTera2) and cervical (HeLa) cancer
cells were unaffected, but pancreatic (BxPC3) and osteosarcoma (U2OS) cancer cells are
sensitized to cisplatin by PARP inhibition by factors of 3.3 and 1.6, respectively (Figure 9,
Table 1). These results were consistently obtained for both the newly developed PARP
inhibitors CEP-A (A) and CEP-6800 (B) as well as a commercially available compound 4-ANI
(C).
A model for the cell line-dependence of sensitization to cisplatin by PARP inhibitors
The sensitization of certain cell lines to cisplatin by PARP inhibitors may be caused by
differences in the processing of platinum-DNA adducts in the absence of PARP activity. This
possibility was investigated by performing photo-cross-linking studies in the presence of the
PARP inhibitor CEP-A, as described above. Experiments using extracts from HeLa cells show
the smallest increase in photo-cross-linking compared to the other types of extracts tested
(Figure 6). Although the total amount of photo-cross-linking does not increase significantly,
one band appears to shift upon addition of PARP inhibitor to the reaction (Figure 5, band 7).
This band might be due to poly(ADP-ribosyl)ated PARP-1, which would migrate slightly more
slowly owing to an increase in molecular weight than the unmodified protein. Alternatively,
it might be due to the recruitment of another DNA-binding protein, such as DNA Ligase III.
In either case, the data indicate that PARP-1 in NTera2, BxPC3, and U2OS nuclear extracts
modifies other proteins to a greater degree, causing them to dissociate from DNA, an effect
not reproduced with HeLa nuclear extracts.
One possible model to tie together the in vitro and in vivo results is that PARP-1 activity in
BxPC3 and U2OS cells dissociates proteins from damaged DNA, allowing the repair apparatus
to access the site. Chemical inhibition of PARP-1 would eliminate this effect, inhibiting repair
and leading to sensitization of the cells to cisplatin. HeLa cells do not experience this
sensitization because PARP-1 activity in HeLa does not significantly affect other platinum
damage-binding proteins. Our photo-cross-linking results in NTera2 nuclear extracts cannot
be explained by this model, but these cells may be too sensitive to PARP inhibitors to allow
an accurate measure of cisplatin sensitization, as already discussed.
V. CONCLUSIONS
Photo-cross-linking studies in the presence of a PARP inhibitor indicate that the activity of
PARP proteins bound to platinum-damaged DNA leads to dissociation of PARP-1 itself, as
well as other proteins, from the damaged duplex. We also discovered that PARPs are better
activated in nuclear extracts by a 1,2-d(GpG) than a 1,3-d(GpTpG) Pt-BP6 intrastrand cross-
link. Several studies in the literature report varying degrees of sensitization of cancer cells to
cisplatin by PARP inhibitors. It has thus far been difficult to determine whether these
inconsistencies are due to the cell lines or the inhibitors used, since both are varied. We present
here the finding that PARP inhibitors sensitize cells to cisplatin in a manner that is cell line-
dependent. In our work, PARP inhibition resulted in the greatest increase in cisplatin sensitivity
for U2OS osteosarcoma cells. NTera2 testicular carcinoma cells do not show this effect, but
are very sensitive to PARP inhibitors themselves. This sensitivity may be due to PARP-1
mutations, which are common in germ cells. We present a model in which PARP inhibitors
are able to sensitize cells to cisplatin if PARP activity in that cell line causes the dissociation
of nuclear proteins from platinum-damaged DNA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AIF, apoptosis-inducing factor; BER, base excision repair; CAM, ceric ammonium molybdate;
NAD+, nicotinamide adenine dinucleotide; MNNG, N-methyl-N-nitro-N-nitrosoguanidine;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NHEJ, nonhomologous
end-joining; PAR, poly(ADP-ribose); PARG, poly(ADP-ribose) glycohydrolase; PARP, poly
(ADP-ribose) polymerase.
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A) The catalytic activity of PARP proteins. PARP proteins catalyze the addition of negatively
charged poly(ADP-ribose) polymers to acceptor proteins using NAD+ as a substrate. B) This
modification is important for DNA repair because the modified proteins will be electrostatically
repelled from the DNA. This activity can be eliminated by the addition of PARP inhibitors.
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Three pathways of PARP activity. The activity of PARP proteins following DNA damage can
lead to DNA repair, apoptosis, or necrosis through independent mechanisms.
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Chemical structures of four PARP inhibitors. CEP-A (A); CEP-6800 (B); 4-amino-1,8-
naphthalimide (4-ANI, C); ABT-888 (D).
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A) The structure of the photoactive cisplatin analogue, Pt-BP6. B) Diagrammatic
representation of chemical cross-linking of proteins with an affinity for platinum-modified
DNA using Pt-BP6 and their identification by gel electrophoresis.
Guggenheim et al. Page 14














Results of photo-cross-linking of Pt-BP6-modified 25-bp duplexes in HeLa nuclear extracts
as a function of increasing concentrations of the PARP inhibitor, CEP-A. For the 1,2-d(GpG)
adduct, the intensity of band 6 increases, while that of band 7 decreases with increasing
concentrations of CEP-A.
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Results of photo-cross-linking of 25-bp duplex containing a 1,2-d(GpG) adduct of Pt-BP6 in
various cancer cell extracts in the presence of the PARP inhibitor, CEP-A. The inhibitor
increases the intensity of photo-cross-linking in each cell line. This effect is quantitated in
Figure 8.
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Results of photo-cross-linking of 25-bp duplex containing a 1,3-d(GpTpG) adduct of Pt-BP6
in various cancer cell extracts in the presence of the PARP inhibitor, CEP-A. The inhibitor
does not have a significant effect in any of the cell lines. This effect is quantitated in Figure 8.
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Intensity of total photo-cross-linking for site-specifically platinated DNA, with or without
addition of the PARP inhibitor CEP-A. The effect of PARP inhibitor CEP-A in photo-cross-
linking experiments reveals an increase in total intensity of photo-cross-linking. The effect is
greater for the 1,2-d(GpG) than the 1,3-d(GpTpG) intrastrand cross-link. The effect is also cell-
line dependent, with HeLa cells exhibiting the smallest increase.
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Results of cytotoxicity assays of cisplatin co-treated with PARP inhibitors in HeLa, NTera2,
BxPC3, and U2OS cells. Cells were treated with cisplatin alone (◆) or co-treated with
maximum tolerated dose of 4-ANI (■), CEP-A (▴) or CEP-6800 (●). The IC50 values are
summarized in Table 1.
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